Document is current
Any future updates will be listed below
-
Authors
Chen, Yunxin https://orcid.org/0000-0001-9039-3474
Gopalakrishnan, Sathish Kumar
Ooi, Melissa
Sultana, Rehena
Lim, Li Hui
Grigoropoulos, Nicholas https://orcid.org/0000-0002-8033-5024
Ong, Shin Yeu https://orcid.org/0000-0003-0192-6975
Xu, Mingge
,
Teh, Ee Mei
Tan, Melinda
Ng, Lawrence
Lee, Yuh Shan
Phipps, Colin
Lim, Francesca Lorraine W. Y.
Hwang, William
Chng, Wee Joo https://orcid.org/0000-0003-2578-8335
Goh, Yeow Tee https://orcid.org/0000-0002-7069-0997
Nagarajan, Chandramouli https://orcid.org/0000-0001-5755-2226
-
Funding
Funding for this research was provided by:
Amgen Inc. | Onyx Pharmaceuticals (ISS 20159882, ISS 20159882, ISS 20159882)
- License Information
-
More Information
Article History
Received: 18 April 2021
Revised: 11 August 2021
Accepted: 17 August 2021
First Online: 3 September 2021
Competing interests
: Y.C., S.G. and C.N. report grants from Amgen during the conduct of the study. W.J.C. reports grants from Celgene, Janssen, ASLAN. Y.C., W.J.C., C.N. reports personal fees from Amgen, Janssen, BMS. W.J.C. reports personal fees from Abbvie, Novartis, Kyan. C.N. reports personal fees for Abbvie, Astra Zeneca, and Takeda. Other authors declare no competing interests.
